Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.
about
Heparin versus placebo for non-ST elevation acute coronary syndromesEverolimus-eluting stents in interventional cardiologyNeoatherosclerosis: Coronary stents seal atherosclerotic lesions but result in making a new problem of atherosclerosisEverolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomesClinical outcomes of second- versus first-generation drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized controlled trialsUnderstanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatmentComparison of Bare-Metal Stent and Drug-Eluting Stent for the Treatment of Patients Undergoing Percutaneous Coronary Intervention for Unprotected Left Main Coronary Artery Disease - Long-Term Result from a Single Center ExperienceRETRACTED: Drug-eluting stents for acute coronary syndrome: a meta-analysis of randomized controlled trialsFirst-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patientsAdvances in stent technologies and their effect on clinical efficacy and safetyManagement of Percutaneous Coronary Intervention Complications.The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trialComparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry.Extracellular matrix molecules facilitating vascular biointegrationRevascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis.The resolute™ integrity zotarolimus-eluting stent in coronary artery disease: a review.Sex differences in long-term outcomes of coronary patients treated with drug-eluting stents at a tertiary medical center.Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysisReduction of endoplasmic reticulum stress inhibits neointima formation after vascular injury.Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study.Second- versus first-generation drug-eluting stents for diabetic patients: a meta-analysis.Increased plasma chymase concentration and mast cell chymase expression in venous neointimal lesions of patients with CKD and ESRDEverolimus-eluting coronary stentsHigh platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention.Coronary stent thrombosis: current insights into new drug-eluting stent designsBifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trialImplementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review.Almanac 2011: stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology.Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease.Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy.CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stentsLong-term performance of the second-generation cobalt-chromium sirolimus-eluting stents in real-world clinical practice: 3-year clinical outcomes from the prospective multicenter FOCUS registry.Novel A20-gene-eluting stent inhibits carotid artery restenosis in a porcine model.Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.Frequency of Vascular Inflammation and Impact on Neointimal Proliferation of Drug Eluting Stents in Porcine Coronary Arteries.A bumpy and winding but right path to domestic drug-eluting coronary stents.A prospective, randomized comparison of promus everolimus-eluting and TAXUS Liberte paclitaxel-eluting stent systems in patients with coronary artery disease eligible for percutaneous coronary intervention: the PROMISE study.One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India.Experience with BioMatrix BES and other DES in all-comers setting: a retrospective overview.
P2860
Q24193744-1FAEFD52-CAA7-4FA8-B019-5DCD2768A9FAQ24630321-5978688C-73B6-485D-A99D-335325275D6BQ26774540-A6F6AE7F-C183-4E83-9610-901CB12167D9Q26798582-2CD16B60-36C0-48A6-8FCC-3F05AD8B83B0Q27023019-436BC0E3-747E-410A-9267-447DECAB253DQ28073031-3F215AE8-B914-4668-A943-7CB4AA75BD25Q28468709-EEF2FB1B-5DD0-4839-B3A2-184E870A81C4Q28536811-D3F37723-8831-41C1-B7A3-541AB9898A45Q28543594-6CAA3478-0107-47F2-869D-1EE8AE1C7CA6Q28972437-67954977-C730-4F1B-B06E-4F593AB0B7C4Q30400083-92104661-6CE4-44A6-9E51-5FE7DF2CA7B0Q30513934-51C82D4E-080D-4ADB-AE0A-1AE5BC1E7276Q31043691-C4606AFA-DD9A-4D5B-B491-D51EEC3734DFQ33649857-9EB7AF54-9DCF-402E-800A-6706B358EF30Q33791885-4A96C7E0-8AB4-447B-9F44-44BD3BED3E66Q33936124-30AAD0E1-2BF6-4757-8626-099204629750Q34182819-8DC303D9-5C97-4B44-BA26-2F73686D39CEQ34452943-0CD6AA26-1AA7-4D8C-8845-2F028339E34AQ34460553-0190275C-FEA0-457B-A7BB-D0127595B85AQ34548825-B9F66270-92AF-4C46-9D6B-56382547FCCFQ34662245-33B9974C-E1FD-4C4F-8EA7-7EED3E8DFE62Q35539717-B3828E63-912A-4D8A-84D8-360EAA2A4759Q36160432-72E50D2A-CC1D-4265-B996-F6BABB84C3B3Q36205878-47A9F33D-06FF-4531-A85A-741517E7BE93Q36514842-0A0B2C64-676D-4174-9FD0-9E749FB0FBCDQ36594779-2A3CD982-977C-437A-BF38-A5E568352D57Q36705836-C31726BA-2641-447B-8ACB-E390A64A4369Q36787252-40BD04DC-989D-4EE8-86C4-81F415841DB6Q36804729-013B23FB-EEDD-4E64-94BE-D4A26E5685F3Q36954581-F8091810-287A-4D0C-AD65-6539DE8E7578Q36995923-5CA4FD78-2606-496A-8302-7BD3B97D9503Q37078060-ED3827F0-D427-4367-BD76-33D2AEC66280Q37121431-ECB6FB88-3074-4AA0-990A-A6A2E9B458FCQ37170542-B2164A8F-5A4E-42B6-90F1-28784B94AF91Q37284036-592CDBB1-16C4-463C-81C7-DE98BDB0F054Q37314517-FB17F8F4-F8A2-4057-A810-811274725D9AQ37316783-D9CAD3C5-DC8B-483D-8E3E-A30B28698DE4Q37329589-F44C8485-43FE-47B5-AD6A-6F2D9A44E441Q37387136-3E94C69D-1497-43AB-9022-2079F3AD3839Q37526533-6CAC2B11-83DA-4F16-9734-D15967CC3D99
P2860
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Second-generation everolimus-e ...... (COMPARE): a randomised trial.
@en
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice
@nl
type
label
Second-generation everolimus-e ...... (COMPARE): a randomised trial.
@en
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice
@nl
prefLabel
Second-generation everolimus-e ...... (COMPARE): a randomised trial.
@en
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice
@nl
P2093
P1433
P1476
Second-generation everolimus-e ...... (COMPARE): a randomised trial.
@en
P2093
Carlos van Mieghem
Dick Goedhart
Elvin Kedhi
Eugene McFadden
Jochem Wassing
Kaiyum Sheik Joesoef
Pieter Cornelis Smits
P304
P356
10.1016/S0140-6736(09)62127-9
P407
P577
2010-01-07T00:00:00Z